Pavmed Inc Stock Alpha and Beta Analysis

PAVM Stock  USD 0.77  0.03  3.75%   
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as PAVmed Inc. It also helps investors analyze the systematic and unsystematic risks associated with investing in PAVmed over a specified time horizon. Remember, high PAVmed's alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to PAVmed's market risk premium analysis include:
Beta
1.58
Alpha
(0.28)
Risk
6.01
Sharpe Ratio
(0.04)
Expected Return
(0.23)
Please note that although PAVmed alpha is a measure of relative return and represented here as a single number, it indicates the percentage above or below your selected benchmark (i.e., Dow Jones Industrial index.) So in this particular case, PAVmed did 0.28  worse than the index. Remember, a high alpha is always good. Beta, on the other hand, measures the volatility (or risk) of an investment. It is an indication of PAVmed Inc stock's relative risk over its benchmark. PAVmed Inc has a beta of 1.58  . As the market goes up, the company is expected to outperform it. However, if the market returns are negative, PAVmed will likely underperform. As of the 26th of February 2025, Book Value Per Share is likely to grow to -2.84. In addition to that, Tangible Book Value Per Share is likely to grow to -3.01.

Enterprise Value

61.98 Million

Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
  
Check out PAVmed Backtesting, PAVmed Valuation, PAVmed Correlation, PAVmed Hype Analysis, PAVmed Volatility, PAVmed History and analyze PAVmed Performance.

PAVmed Market Premiums

Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. PAVmed market risk premium is the additional return an investor will receive from holding PAVmed long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in PAVmed. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate PAVmed's performance over market.
α-0.28   β1.58

PAVmed expected buy-and-hold returns

Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of PAVmed's Buy-and-hold return. Our buy-and-hold chart shows how PAVmed performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.

PAVmed Market Price Analysis

Market price analysis indicators help investors to evaluate how PAVmed stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading PAVmed shares will generate the highest return on investment. By understating and applying PAVmed stock market price indicators, traders can identify PAVmed position entry and exit signals to maximize returns.

PAVmed Return and Market Media

The median price of PAVmed for the period between Thu, Nov 28, 2024 and Wed, Feb 26, 2025 is 0.67 with a coefficient of variation of 20.59. The daily time series for the period is distributed with a sample standard deviation of 0.15, arithmetic mean of 0.75, and mean deviation of 0.13. The Stock received substential amount of media coverage during this period.
 Price Growth (%)  
       Timeline  
1
PAVmed Closes on Sale of Lucid Diagnostics Senior Secured Convertible Notes
11/29/2024
2
PAVmed stock plunges to 52-week low, touches 0.6 - Investing.com
12/18/2024
3
Lucid Inks New Partnership With VITALExam Stock to Gain - MSN
12/26/2024
4
Disposition of 12450 shares by Aklog Lishan of PAVmed at 1.6 subject to Rule 16b-3
01/02/2025
5
PAVmed shareholders approve stock issuance and charter amendment
01/15/2025
6
PAVmed stock touches 52-week low at 0.57 amid market challenges - MSN
02/07/2025
7
PAVmed regains Nasdaq compliance
02/18/2025
8
Lucid Diagnostics Regains Compliance with Nasdaq Minimum Bid Price Requirement
02/25/2025

About PAVmed Beta and Alpha

For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including PAVmed or other stocks. Alpha measures the amount that position in PAVmed Inc has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
 2024 2025 (projected)
Dividend Yield2.98E-42.65E-4
Price To Sales Ratio13.9713.27

PAVmed Upcoming Company Events

As portrayed in its financial statements, the presentation of PAVmed's financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, PAVmed's leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of PAVmed's public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of PAVmed. Please utilize our Beneish M Score to check the likelihood of PAVmed's management manipulating its earnings.
12th of March 2024
Upcoming Quarterly Report
View
21st of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
12th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

Build Portfolio with PAVmed

Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.

Build Diversified Portfolios

Align your risk with return expectations

By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
When determining whether PAVmed Inc is a strong investment it is important to analyze PAVmed's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact PAVmed's future performance. For an informed investment choice regarding PAVmed Stock, refer to the following important reports:
PAVmed technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
A focus of PAVmed technical analysis is to determine if market prices reflect all relevant information impacting that market. A technical analyst looks at the history of PAVmed trading pattern rather than external drivers such as economic, fundamental, or social events. It is believed that price action tends to repeat itself due to investors' collective, patterned behavior. Hence technical analysis focuses on identifiable price trends and conditions. More Info...